Surface Ophthalmics
Surface Ophthalmics, a biotech firm, innovates ocular disease treatments using patented Klarity delivery.
Founded
2016Surface Ophthalmics, a biotech firm, innovates ocular disease treatments using patented Klarity delivery.
Founded in 2017 and based in Pleasanton, California, Surface Ophthalmics is a biotechnology company dedicated to developing advanced therapeutics for ocular diseases. The company's core mission is to improve the treatment of dry eye syndrome (DES) and other ocular surface diseases through innovative solutions. Surface Ophthalmics' product pipeline includes three proprietary drug candidates that leverage Klarity, a patented delivery vehicle, offering both prescription and over-the-counter eye drops.
Surface Ophthalmics has garnered attention for its pioneering approach in the ophthalmic field. Key figures associated with the company include experienced professionals in biotechnology and pharmaceuticals. The firm has achieved significant milestones in its drug development pipeline, contributing to the betterment of treatment options for underdiagnosed and undertreated conditions like DES. Surface Ophthalmics continues to make a notable impact on the ocular health community through its commitment to innovation and patient care.
Companies similar to Surface Ophthalmics include Surface Pharmaceuticals, TearClear, Ocular Therapeutix and Ocular Science.
Surface Ophthalmics was founded in 2016.
Surface Ophthalmics' headquarters is located in Pleasanton, CA, US.
Surface Ophthalmics' most recent funding round was for $25M (USD) in June 2021.
As of Jun 10, 2021, Surface Ophthalmics has disclosed funding of $40M (USD). Undisclosed round amounts are excluded.
Surface Ophthalmics has 5 employees as of Feb 5, 2024.
Ocular Science
ocularscience.com
